-->

Cell and gene therapy for cancer, autoimmune diseases and genetic disorders

"Submit your medical reports for complimentary analysis and feedback."

Get Started Know More
CAR T Cell therapy in autoimmune disorders

 

 

At CancerFax, we are unwavering in our commitment to supporting patients at every step of their cancer journey. Our dedication goes beyond connecting you to world-class treatments — we ensure you have access to the most advanced therapies, including cutting-edge CAR T-Cell therapy, gene therapy, and groundbreaking clinical trials.

We stand by our promise: we do not rest until our patients achieve complete remission. With personalized care plans, expert medical guidance, and strong collaborations with leading hospitals and research centers worldwide, we fight alongside you.

Whether you’re exploring innovative treatment options or seeking a second opinion, CancerFax is your trusted partner, guiding you with compassion and expertise. Because for us, remission isn’t just an aspiration — it’s our commitment.

Your fight is our mission.

Cancer Cell Therapies, Gene Therapy
And Clinical Trials

CancerFax

1.

Cancer Cell Therapies

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gamma-Delta T-Cell therapy, TIL therapy, NK Cell therapy, and clinical trials. This life-saving service empowers patients to explore new frontiers in cancer treatment while providing them with comprehensive information on trial eligibility criteria, locations, and enrollment processes.

Cancer treatment abroad with cancerfax

2.

Gene Therapy

CancerFax connects patients with leading hospitals and experts offering advanced gene therapy solutions. With personalized guidance, assistance in medical travel, and access to cutting-edge treatments, CancerFax ensures patients receive the best possible care, offering new hope for those suffering from genetic blood disorders like sickle cell anemia and thalassemia.

Advanced stage lung cancer treatment

3.

Clinical Trials

Our company specializes in cancer clinical trial services, facilitating access to groundbreaking research and treatment options. We connect patients with cutting-edge trials, fostering hope and progress in the fight against cancer. With a commitment to improving lives, we’re at the forefront of advancing cancer care through clinical innovation.

Find a Clinical Trial That Fits You!

Looking for innovative treatment options? Clinical trials offer access to the latest therapies under expert supervision.
Find a trial that matches your condition and take the next step today.

Gene Therapy for X-Linked Severe Combined Immunodeficiency. 

Intrathecal and Intravenous Lentiviral Gene Therapy for X-linked Adrenoleukodystrophy (X-ALD).

Use of BAH243 lentiviral vector for gene therapy in sickle cell anemia.

Gene Therapy of Beta Thalassemia Using a self-inactivating lentiviral vector.

An open-label clinical trial of ex vivo beta-globin lentiviral vector transduction of Autologous CD34+HSPCs (Vebeglogene Autotemcel) for the Treatment of Transfusion Dependent Beta-thalassemia Patients. 

An Exploratory Study on the Treatment of Advanced Solid Tumors by Secretory PD1 Nanoantibody Targeting Mesothelin Fast CAR T Cells. 

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With HER2+ Locally Advanced and/ or Metastatic Solid Tumors
Conditions.

Chimeric Antigen Receptor T Lymphocytes (CAR-T) Targeting CEA in the Treatment of CEA Positive Clinical Study of Advanced Malignant Solid Tumors.

Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors.

Apply for trials

Clinical trials

CancerFax specializes in guiding individuals through the complex process of enrolling in cancer clinical trials. With unwavering dedication, we connect patients to cutting-edge research and treatment options, offering a lifeline of hope in their battle against cancer. Our team of compassionate experts navigates the intricate world of clinical trials, ensuring that every patient receives personalized support and guidance. We’re committed to empowering patients, giving them access to innovative therapies, and advancing the fight against cancer. At our company, we believe that participation in clinical trials can be a vital step towards a brighter future.

Check details on

Cancer Clinical Trials

CAR T-Cell Therapy

Much attention is now focused on stem cell therapy, the revolutionary line of treatment that involves the exploitation of the rich potential of stem cells in restoring damaged tissues and organs. Stem cells are characterized by the ability to acquire the features of different cells, hence their benefit in various applications in regenerative medicine. Extracted from mediators such as bone marrow, fat tissue, or umbilical cord blood, the stem cells are then injected into the affected areas. The promise of this mode of therapy for stem cells stretches the treatment options to include spinal cord injury, heart diseases, and neurodegenerative disorders, rekindling hope among patients with hitherto incurable diseases.

Check details on

CAR T-Cell Therapy

Gene Therapy

Gene therapy is a new frontier of medicine that involves treating or preventing diseases by altering the genetic material of an individual. This technique includes introducing, removing, or altering genetic material in the cells of an individual. Correcting defective genes or providing new genes through this technique consequently corrects the very basis of genetic disorders and diseases. This has been very promising in treating certain diseases and disorders passed down through generations, varieties of cancer, and viral infections caused by viruses; however, most of these applications are still experimental. Successful treatments have been developed for conditions such as spinal muscular atrophy and some forms of inherited blindness, which are milestones in medical science.

Check details on

Gene Therapy
Cancer treatment in India

Stem Cell Therapy

Much attention is now focused on stem cell therapy, the revolutionary line of treatment that involves the exploitation of the rich potential of stem cells in restoring damaged tissues and organs. Stem cells are characterized by the ability to acquire the features of different cells, hence their benefit in various applications in regenerative medicine. Extracted from mediators such as bone marrow, fat tissue, or umbilical cord blood, the stem cells are then injected into the affected areas. The promise of this mode of therapy for stem cells stretches the treatment options to include spinal cord injury, heart diseases, and neurodegenerative disorders, rekindling hope among patients with hitherto incurable diseases.

Check details on

Stem Cell Therapy

Gamma Delta T-Cell Therapy

Gamma delta T-cell therapy is the new frontier of cancer therapy and capitalizes on novel features of gamma delta T-cells, a unique subset of immune system T-cells. In contrast to conventional T-cells, gamma delta T-cells have the ability to recognize and kill a wide range of cancer cells without prior sensitization. This is a therapy in which gamma delta T-cells from a patient or donor are isolated and expanded, then refinfused into patients to target and destroy cancer cells. Gamma delta T-cell therapy holds immense promise because it holds the potential to target different types of tumors; it may cause fewer side effects compared to other forms of immunotherapy. It is an active area of research in establishing its efficacy for the treatment of various types of cancers.

Check details on

Gamma Delta T-Cell Therapy
Cancer treatment in south korea

TIL Therapy

TIL therapy represents a sophisticated kind of immunotherapy that induces a patient's immune cells in the fight against cancer. TILs are immune cells that naturally migrate into a tumor. They are taken from the patient's tumor and then expanded and activated in a laboratory for reinfusion into the patient. These expanded TILs are more potent and efficient at homing in on the tumor cells to kill them. TIL therapy has been found to be very promising in the treatment of metastatic melanoma and advanced cancers by using the natural defenses of the body against malignancies more effectively.

Check details on

TIL Therapy

Gene therapy for sickle cell anemia

Gene therapy for sickle cell anemia offers a promising solution by targeting the root cause of the disease. This innovative treatment involves modifying the patient's genetic code to correct the defective hemoglobin gene responsible for the condition. By introducing functional genes or editing the existing ones, gene therapy aims to produce healthy red blood cells, potentially providing a long-term cure and improving the quality of life for patients.

Gene therapy for sickle cell anemia

CAR T-Cell therapy in India

India’s innovative CAR-T cell therapy, NexCAR19, is the country’s initial indigenous strategy to fight cancer. Created by ImmunoACT, a branch of IIT Bombay, this advanced therapy utilizes genetically modified T-cells to target and eliminate cancerous cells, specifically in blood malignancies such as leukemia and lymphomas. Initial trials demonstrate potential, with around 50% obtaining total remission, particularly in juvenile cases of B-cell acute lymphoblastic leukemia. NexCAR19 shows decreased neurotoxicity in comparison to foreign options, indicating possible benefits over current treatments. India plans to provide this treatment at a reduced cost compared to worldwide prices, starting at roughly INR 30–40 lakhs and aiming to lower it to INR 10–20 lakhs with regulatory approval.

Check details on

CAR T-Cell Therapy In India
CAR T cell therapy in China for multiple myeloma

CAR T-Cell therapy in China

CAR T-cell therapy in China has seen remarkable advancements in recent years, mirroring the global progress in this cutting-edge cancer treatment. With more than 700 ongoing clinical trials, China leads the development of CAR T-Cell therapy. China has swiftly embraced CAR T-cell therapy, offering new hope to patients battling various cancers, including leukemia and lymphoma. Several Chinese hospitals and research institutions are actively conducting clinical trials and providing CAR T-cell therapy to eligible patients. The country’s robust infrastructure and access to a vast patient population have accelerated research and development efforts. With a commitment to advancing this innovative therapy, China is significantly contributing to the global landscape of cancer immunotherapy, enhancing treatment options for patients nationwide.

Check details on

CAR T-Cell Therapy In China
CAR T Cell therapy in Israel

CAR T-Cell therapy in Israel

In Israel, CAR T-cell therapy has emerged as a transformative approach in the fight against cancer. The country’s healthcare sector, known for its world-class research and innovation, has made significant strides in developing and implementing CAR T-cell therapies for patients with hematologic malignancies and solid tumors. Leading medical institutions and biotechnology companies in Israel are actively involved in clinical trials and research projects, pushing the boundaries of CAR T-cell therapy. Israel’s collaborative environment and cutting-edge technologies have positioned it as a global player in advancing immunotherapy, offering new treatment avenues and hope for cancer patients, both domestically and worldwide.

Check details on

CAR T-Cell Therapy In Israel

CAR T-Cell therapy in Singapore

CAR T-cell therapy has made significant inroads in Singapore’s healthcare landscape, offering a promising avenue for cancer treatment. The country’s advanced medical infrastructure and research capabilities have enabled the development and application of this cutting-edge immunotherapy. Patients in Singapore now have access to CAR T-cell therapy for various blood cancers, marking a transformative shift in oncology care. Local healthcare institutions are actively involved in clinical trials and collaborations with global experts, ensuring patients receive world-class treatment. With its commitment to innovation and patient-centric care, Singapore is playing a pivotal role in advancing CAR T-cell therapy, providing new hope to cancer patients in the region and beyond.

Check details on

CAR T-Cell Therapy In Singapore
Testimonials

What patients say about us?

We love our users because they love us. Check out some of the love they’ve sent our way

“I am writing this testimonial to express my profound gratitude for the life-changing experience I had with the CancerFax team, who introduced me to CAR T-cell therapy in China. My journey battling cancer took a hopeful turn when I was introduced to this groundbreaking treatment, and it has been nothing short of remarkable. Before CAR T-cell therapy, I had exhausted conventional treatments without much success. My situation was dire, and hope was fading. However, my decision to undergo CAR T-cell therapy in China was a turning point. The level of care and expertise I received was exceptional. The medical team was not only highly skilled but also incredibly compassionate, providing me with the support and reassurance I needed during this challenging time.”

Bjorn Simenson

Multiple Myeloma Survivor, Norway

Our customers love us!

CancerFax
5.0
Based on 28 reviews
powered by Google
review us on
Coach Lifeskills Unlimited Nitin Rishi
09:43 03 May 24
Very impressive and fine service and care .Keep up the good work going !!
Subodh Bajaj
04:12 02 May 24
CancerFax is doing great job CEO personally take care of each & every patient
Mitul Gadhiya
09:29 01 May 24
I cannot speak highly enough of the team at CancerFax. From the moment I reached out, their team displayed unmatched professionalism, empathy, and expertise. Their services are comprehensive, covering everything from personalized treatment recommendations to emotional support for both patients and their families. CancerFax is more than just a service provider; they are a lifeline for cancer patients and their loved ones. I am profoundly grateful for everything they have done for me, and I wholeheartedly recommend their services to anyone facing a cancer diagnosis.
Aftab Khan
02:53 27 Apr 24
An absolutely marvellous venture, with a committed set of professionals who go about their tasks with zeal and a go-getter attitude! More power to cancerfax!
Sujit Singh
02:14 24 Apr 24
I needed some help with treatment and the CEO personally helped line up the appointments with the best doctors. Very thankful. All the best.
ASHISH SONI
05:11 23 Apr 24
Your website is doing wonderful work. Business with ethics, service, humanity sustainability and social motives always next to Godliness. Keep doing good work. Excellent Team CancerFax.

From Our Authors

Read the insights from the world's leading authorities in their respective fields.

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
Susan Hau

The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor blocks tumor growth and alleviates symptoms, providing a surgery-free way to control TGCT. The approval is based on clinical trial evidence of substantial tumor shrinkage and symptom relief. The approval is a significant step forward in TGCT treatment, enhancing the quality of life for these patients.

Susan Hau March 13, 2025
Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
Nishant Mittal (PhD)

The FDA approved brentuximab vedotin in combination with lenalidomide and rituximab to treat relapsed or refractory large B-cell lymphoma (LBCL). The combination represents a new option for treatment after failure of initial therapies. The approval follows the presentation of data from clinical trials showing that this combination improved patient outcomes. This combination is a new strategy in the management of LBCL and provides a greater number of available treatments for those with few choices.

Nishant Mittal (PhD) March 13, 2025
Mirdametinib is approved by the USFDA for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
Nishant Mittal (PhD)

The FDA has approved mirdametinib for adult and pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. The MEK inhibitor addresses tumor growth, giving symptomatic NF1 patients a non-surgical alternative for this rare genetic condition. Approval comes based on clinical trial evidence of dramatic tumor shrinkage and symptom reduction. This represents a significant step forward in NF1 treatment, giving new hope to patients.

Nishant Mittal (PhD) March 13, 2025
Treosulfan with fludarabine is approved by the USFDA as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS
Susan Hau

The FDA approved the **treosulfan and fludarabine** preparative regimen for **allogeneic hematopoietic stem cell transplantation (alloHSCT)** in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The regimen provides an alternative conditioning strategy with a balance of efficacy and tolerability for transplant patients. Approval was made based on clinical trial evidence supporting improved outcomes. This is an important step forward in transplant conditioning for high-risk AML and MDS patients.

Susan Hau March 13, 2025
Fam-trastuzumab deruxtecan-nxki is approved by the USFDA for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer
Susan Hau

  On January 27, 2025, the Food and Drug Administration sanctioned fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as identified by an FDA-approved assay, that has advanced following one

Susan Hau March 13, 2025
Datopotamab deruxtecan-dlnk is approved by the USFDA for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Nishant Mittal (PhD)

The FDA has approved datopotamab deruxtecan (Dato-DXd) to treat unresectable or metastatic HR-positive, HER2-negative breast cancer following previous endocrine treatment and chemotherapy. The drug treats the disease by delivering targeted chemotherapy, enhancing the outcome for patients with advanced disease. Approval has been made based on clinical trial results demonstrating efficacy and safety. This is an important step towards providing greater treatment options for patients who have limited choices in metastatic breast cancer.

Nishant Mittal (PhD) March 13, 2025

Frequently asked questions.

Find below the answers to the most common questions patients have about cancer treatment.

What are some advanced treatment options available for cancer?

Advanced cancer treatment options include:

  • Immunotherapy: This treatment uses the body’s immune system to fight cancer cells. It can be highly effective in certain cancers by boosting the immune response against cancer cells.

  • Targeted Therapy: This involves drugs that specifically target genetic mutations or abnormalities within cancer cells, minimizing damage to healthy cells.

  • Precision Medicine: By analyzing a patient’s genetic makeup and tumor characteristics, doctors can tailor treatments for specific cancer types, leading to more effective outcomes.

  • CAR T-cell Therapy: This innovative therapy involves genetically modifying a patient’s T-cells to recognize and attack cancer cells, particularly in blood cancers like leukemia, multiple myeloma, and lymphoma.

  • Gemma-Delta T-Cell Therapy: Gamma-delta T cell therapy harnesses these unique immune cells to target and destroy cancer cells, offering a promising new cancer treatment.

  • TIL therapy:  Tumor-Infiltrating Lymphocyte (TIL) therapy involves harvesting and expanding a patient’s own immune cells to target and attack cancer cells effectively.

  • NK Cell therapy:  Natural Killer (NK) Cell therapy utilizes the body’s NK cells to identify and destroy cancer cells, enhancing immune response against tumors.

Advanced cancer treatments offer several benefits:

  • Enhanced Effectiveness: Targeted therapies and immunotherapies are often more effective and precise, resulting in better outcomes and fewer side effects.

  • Personalized Approach: Advanced treatments are often tailored to an individual’s genetic and molecular profile, maximizing effectiveness while minimizing unnecessary treatment.

  • Reduced Side Effects: Compared to traditional chemotherapy and radiation, advanced therapies can have fewer severe side effects, improving quality of life during treatment.

  • Increased Survival Rates: Many advanced treatments have shown to significantly improve survival rates and long-term outcomes, especially in cases of advanced or metastatic cancer.

Accessing advanced cancer treatments involves several steps:

  • CancerFax: Send us your medical reports on email or WhatsApp and our medical team will guide you with best available advanced cancer treatment options.

  • Consultation with Oncologist: Patients should discuss advanced treatment options with their oncologist, who can provide information on available therapies and suitability for individual cases.

  • Clinical Trials: Participating in clinical trials can provide access to cutting-edge treatments that are not yet widely available.

  • Health Insurance Coverage: Patients should check with their health insurance provider to understand coverage for advanced treatments and associated costs.

  • Referral to Specialized Centers: Referral to specialized cancer centers or hospitals known for advanced cancer care can ensure access to a wider range of treatment options.

  • Patient Advocacy Groups: These groups can provide resources, support, and information on accessing advanced treatments and navigating the healthcare system effectively. Join our Facebook group, Conquering cancer.

CancerFax is connected to some of the world’s and the USA’s top cancer hospitals. Check our list of hospitals above and select the one that fits your requirements. Our medical team can also help you select the one that fits your requirements and needs. Check out the list of the best cancer hospitals in the USA. .

You need to provide the following medical records:
  • 1. Medical summary
  • 2. Latest PET CT scan
  • 3. Latest blood reports
  • 4. Biopsy report
  • 5. Bone marrow biopsy (For blood cancer patients)
  • 6. All the scans in DICOM format
Apart from this you also need to sign the patient consent form provided by CancerFax.
Online cancer consultation refers to the process of obtaining medical advice, a diagnosis, and treatment recommendations for cancer-related issues via virtual platforms. It enables patients to communicate remotely with oncologists and other healthcare professionals via video calls and telemedicine technology. Online consultations offer convenience and accessibility, especially for those with mobility issues or who reside in remote areas.
Using telemedicine technology, online cancer consultations connect patients and healthcare professionals remotely. Patients can discuss their cancer-related concerns, share medical records, and obtain expert advice via secure video calls or teleconferencing platforms. Doctors can examine the provided information remotely and provide a diagnosis, treatment recommendations, and ongoing support. If need be, specialists can also connect with local treating doctors to formulate a treatment plan that is most suitable for the patient.
Yes, you get a prescription and a complete report / protocol on the course of treatment required.
You do not need any equipment for an online consultation; you just need a pathology consultation and a written report. For video and telephonic consultations, you will need a smart phone with good internet speed.

CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is an innovative immunotherapy approach. It involves collecting a patient’s own T cells, genetically modifying them to target cancer cells more effectively, and then infusing these modified cells back into the patient’s body. The CAR T cells can recognize and attack cancer cells with precision. Check out the complete details on CAR T-Cell therapy. .

Eligibility for CAR T-cell therapy depends on various factors, including the type of cancer, its stage, and the patient’s overall health. Typically, CAR T-cell therapy is considered for patients with certain types of relapsed or refractory blood cancers, such as leukemia or lymphoma, who have not responded to standard treatments. Your oncologist will assess your specific case to determine eligibility.
CAR T-cell therapy can have side effects, including cytokine release syndrome (CRS) and neurologic side effects. CRS can cause fever, flu-like symptoms, and, in severe cases, organ dysfunction. Neurologic side effects may include confusion or seizures. Healthcare professionals are closely monitoring and managing these side effects. It’s essential to discuss potential risks and benefits with your medical team.
A clinical trial is a research study designed to test new treatments or interventions for cancer. By participating, you may receive access to cutting-edge therapies that could potentially be more effective than standard treatments. Clinical trials also contribute to advancing medical knowledge and improving future cancer care.
You can start by discussing clinical trial options with your oncologist or healthcare provider. They can recommend trials based on your specific cancer type, stage, and medical history. Additionally, websites like ClinicalTrials.gov and patient advocacy organizations often provide searchable databases of ongoing trials.
Benefits may include access to innovative treatments, close medical monitoring, and potentially improved outcomes. Risks can vary but may include side effects from experimental treatments or the chance that the new treatment doesn’t work as well as standard care. It’s important to thoroughly discuss both risks and benefits with your healthcare team before making a decision.
Not all clinical trials use placebos, and many involve comparing the experimental treatment to the current standard of care. If a placebo is used, participants are informed beforehand, and ethical guidelines ensure that no one is denied necessary treatment. Your healthcare team will explain the trial design and whether a placebo is involved.
Clinical trials are conducted with a strong emphasis on patient safety. Ethics committees and regulatory organizations closely monitor them and enforce strict protocols. You will be informed about potential risks and monitored throughout the trial. You can withdraw from a trial at any time if you have concerns about safety or other issues.
Typically, the clinical trial sponsor is responsible for covering the costs of the experimental treatment and study-related tests. However, you may still be responsible for standard medical expenses not related to the trial, such as regular doctor visits or non-experimental treatments. It’s essential to discuss financial aspects with the trial coordinator and your insurance provider to understand what is covered and any potential out-of-pocket expenses. Many insurance plans now cover the routine costs of clinical trial participation.
CAR T-cell therapy is typically a one-time treatment. However, some patients may require additional infusions or other treatments if their cancer relapses or if there’s a need for long-term follow-up care. Your treatment plan will be tailored to your specific situation.
After CAR T-cell therapy, you will be closely monitored for potential side effects and to assess the treatment’s effectiveness. Success rates can vary depending on the type and stage of cancer. CAR T-cell therapy has shown promising results in some patients with relapsed or refractory blood cancers, leading to complete remissions. However, individual responses may vary, and it’s essential to discuss your prognosis with your medical team.

Yes, some companies have started CAR T-Cell therapy in India with the help of vectors from China and Malaysia. However, this therapy is still under clinical trials. Patient consent forms and doctor advice are solicited before you go for these trials.

The cost of CAR T-cell therapy varies from country to country. Here is the approximate cost in different countries. USA- $ 600,000-700,000 USD China – $ 60,000-90,000 USD India – $ 60,000-90,000 USD Israel – $ 85,000-100,000 USD Singapore – $ 700,000-750,000 SGD

In China, CAR T-cell therapy is primarily approved and used for the treatment of hematologic malignancies, such as lymphoma, leukemia, and myeloma.
While there are some clinical trials and research efforts exploring CAR T-cell therapy for solid tumors, progress in this area has been slower compared to hematologic malignancies.

As per the information available, CAR T-cell therapies for solid tumors account for only 9% of the total CAR T-cell therapies being developed in China.

The effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy in China has been compared to alternative treatments through extensive clinical trials and research. As of 2022, China has a larger number of CAR-T clinical studies than the United States, particularly in hematologic malignancies. Two CAR-T therapies, axicabtagene ciloleucel (Yescarta) and relmacabtagene autoleucel (Carteyva), have been approved in China by the National Medical Products Administration (NMPA). CAR-T therapy in China has demonstrated efficacy in various hematologic malignancies, including B-cell acute lymphoblastic leukemia (ALL), lymphoma, and multiple myeloma (MM). However, challenges remain, such as the high cost, time-consuming production process, and immune-related adverse events. To address these issues, Chinese researchers are developing strategies to optimize CAR-T therapy, including the development of allogeneic CAR-T products and the use of alternative costimulatory domains. In summary, CAR-T therapy in China has shown promising results in hematologic malignancies, with a larger number of clinical trials compared to the United States. However, challenges remain, and further research is needed to optimize the therapy and expand its use to solid tumors.

CAR T-Cell therapy cost in China varies between 45,000 USD and 90,000 USD. The overall cost depends upon the hospital chosen and the number of target antigens chosen.  The cost of the approved CAR-T cell therapies in China is generally around 1,200,000 Chinese yuan (CNY), which is equivalent to approximately US$170,000. The cost of Cilta-Cel, FUCASO (NMPA-approved) for multiple myeloma varies between 250,000 and 300,000 USD. The cost-effectiveness of CAR-T cell therapies in China varies depending on the specific therapy and the patient’s condition.

Everything you need to know about
different types of cancer

Cancer Types

Breast Cancer

Lung Cancer

Oral Cancer

Thyroid Cancer

Blood Cancer

Top Cancer Hospitals

ESTD: 1941

No. of beds: 1200

MD Anderson Cancer Center, USA

The MD Anderson Cancer Centre is a recognised organisation that leads the globe in cancer treatment, research, and education. It was founded in 1941 and is based in Houston, Texas. It has long been a leader in cancer research and treatment. The facility is named for Monroe Dunaway Anderson, a wealthy businessman and philanthropist who had the idea to build a comprehensive cancer centre that would revolutionize how cancer is understood and treated.

ESTD: 2001

No. of beds: 380

Parkway Cancer Centre, Singapore

Parkway Hospitals attracts international patients because of its world-class medical facilities and expertise. Parkway Hospitals is Asia’s largest private healthcare provider.

ESTD: 2003

No. of beds: 400

Beijing Gobroad Hospital, China

Beijing Gobroad Boren Hospital is a privately owned medical facility dedicated to advanced medical technology, compassionate care, and patient satisfaction, prioritizing the well-being of patients above all else. We incorporate the advanced knowledge system, diagnostic and treatment procedures, sustainable medical training, patient education, hospital administration, and service concept from the top-tier medical group in the United States, Mayo Clinic.

Top Oncologists

Dr Erica Mayor Dana Farber Cancer Hospital

Dr. Erica L. Mayer

Boston, United States

Director, Clinical Research
Experience: 23

Dr Ang Peng Tiam Parkway Hospital Singapore

Dr. Ang Peng Tiam

Singapore

Medical Director and Senior Consultant Medical Oncology , Experience: 24 Years

Dr Arnon Nagler Sheba Hospital Israel

Prof. Arnon Nagler

Tel Aviv, Israel

Director of the Division of Hematology , Experience: 34 Years

Dr Peggy Pehua Lu Beijing China

Dr. Peihua Peggy Lu

Beijing, China

Medical Executive President of Lu Daopei Hospital, Beijing, China , Experience: 27 Years

News & Blog

Latest in Cancer

View all articles
Analytics
February 09, 2024

NMPA approves the FUCASO treatment for multiple myeloma in China
Analytics
February 09, 2024

NMPA approves the FUCASO treatment for multiple myeloma in China
Analytics
February 09, 2024

Clinical Trials Of CAR T-Cell Therapy In China Has Shown Remarkable Success
Analytics
February 09, 2024

A Closer Look At Recent Cancer Clinical Trials In China And New Cancer Drug Approved
Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟